See more : RioCan Real Estate Investment Trust (RIOCF) Income Statement Analysis – Financial Results
Complete financial analysis of Seres Therapeutics, Inc. (MCRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seres Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pizu Group Holdings Limited (8053.HK) Income Statement Analysis – Financial Results
- Monarch Casino & Resort, Inc. (MCRI) Income Statement Analysis – Financial Results
- Mittal Life Style Limited (MITTAL.NS) Income Statement Analysis – Financial Results
- Hailir Pesticides and Chemicals Group Co.,Ltd. (603639.SS) Income Statement Analysis – Financial Results
- Hudson Executive Investment Corp. III (HIIIU) Income Statement Analysis – Financial Results
Seres Therapeutics, Inc. (MCRB)
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.10M | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 704.00K | 1.00M | 1.73M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 728.00K | 10.72M | 0.00 | 0.00 |
| Gross Profit | 125.62M | 6.12M | 143.20M | -57.36M | -45.64M | -67.69M | -57.36M | -60.22M | -728.00K | -10.72M | 0.00 | 0.00 |
| Gross Profit Ratio | 99.44% | 85.91% | 98.80% | -172.68% | -132.26% | -239.46% | -178.68% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 38.10M | 10.72M | 4.81M | 2.08M |
| General & Administrative | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Other Expenses | 0.00 | 1.00M | -1.73M | 981.00K | 1.07M | 170.00K | 425.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 233.60M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Cost & Expenses | 234.31M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Income | 7.30M | 3.06M | 2.87M | 946.00K | 1.03M | 0.00 | 0.00 | 2.23M | 638.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.18M | 6.02M | 2.91M | 2.92M | 502.00K | 1.17M | 1.59M | 969.00K | 555.00K | 0.00 | 42.00K | 0.00 |
| Depreciation & Amortization | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728.00K | 190.00K | 88.00K | 25.00K |
| EBITDA | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBITDA Ratio | -74.65% | -3,425.04% | -43.24% | -259.53% | -197.90% | -354.77% | -262.11% | -396.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.40M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Operating Income Ratio | -85.48% | -3,458.05% | -44.50% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.74M | -3.67M | -1.09M | -997.00K | 1.60M | 1.34M | 2.02M | 1.26M | 76.00K | -1.63M | -50.00K | -93.00K |
| Income Before Tax | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Income Before Tax Ratio | -90.02% | -3,509.50% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804.00K | 1.63M | 42.00K | 0.00 |
| Net Income | -113.72M | -253.82M | -61.50M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Net Income Ratio | -90.02% | -3,560.94% | -42.43% | -260.29% | -186.19% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| EPS Diluted | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| Weighted Avg Shares Out | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Weighted Avg Shares Out (Dil) | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports